Dose and local efficacy analysis of iodine-125 seed implantation therapy for lung tumors

doi:10.21203/rs.3.rs-4697814/v1

Download PDF

Research Article

Dose and local efficacy analysis of iodine-125 seed implantation therapy for lung tumors

https://doi.org/10.21203/rs.3.rs-4697814/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Objective

To explore the dose and local efficacy of iodine-125 seed implantation therapy for lung tumors.

Methods

The clinical data of 85 patients with lung tumors who underwent iodine-125 seed implantation therapy were retrospectively analyzed. The impact of prescription dose D90 (minimum peripheral dose received by the 90% target volume) on the local treatment effect six months after seed implantation was analyzed, and the critical value for predicting efficacy was determined. Factors affecting the local complete response (CR) rate six months after surgery were also analyzed.

Results

The local control rate six months after treatment was 89.41% (76/85), and the overall response rate (CR + PR) was 70.59% (60/85), with a CR rate of 31.76% (27/85). Patients with a postoperative D90 > 140 Gy had a significantly greater local CR rate. Multivariate analysis revealed that postoperative D90 and tumor size were independent prognostic factors for achieving CR six months after lung tumor seed implantation.

Conclusion

Iodine-125 seed implantation therapy is effective for lung tumors. Tumor size (P = 0.0003) and postoperative D90 (P = 0.0005) were found to be independent prognostic factors for achieving postoperative CR after lung tumor seed implantation.

iodine-125 seed

lung tumor

D90

tumor size

prognostic factors

The incidence and mortality rates of lung cancer remain the highest worldwide [1]. Surgical tumor resection is recognized as the most effective treatment for early- and middle-stage lung cancer. However, by the time lung cancer is diagnosed, patients are often already in the middle or late stages. Owing to their physical condition and other factors, more than 50% of these patients are no longer suitable candidates for radical surgery [2]. Currently, the 5-year survival rate of patients with lung cancer is only 19.7% [3]. Due to their unique anatomical characteristics, the lungs are the second most common organ for tumor metastasis, with approximately 20%–54% of patients having secondary lung lesions [4-5]. Seed implantation has been confirmed to be an effective treatment method for lung tumors [6-8]. Most current studies on seed implantation focus on its safety and local effectiveness but do not conduct in-depth research on the local complete remission rates of this seed treatment. This study further explored and analyzed the dosage and local efficacy of seed implantation in lung tumors.

1.1. Clinical Data

This retrospective analysis included 85 patients with lung cancer and metastatic lung cancer who were admitted to our hospital between January 2017 and March 2021. The primary disease conditions are detailed in Table 1. Among the 85 patients, 64 were male and 21 were female, with an average age of 64.1 (range 41–90) years. Of these, 47 patients received seed implantation combined with systemic treatment, while 38 did not receive systemic treatment. Systemic treatment included chemotherapy, targeted therapy, and immunotherapy, among others. Patients who were pathologically confirmed to have lung cancer through surgery or percutaneous biopsy before treatment and who received standardized comprehensive treatments such as external radiation therapy and chemotherapy, who had confirmed lung tumors before treatment through CT or positron emission tomography (PET)-CT, who were evaluated by two associate chief physicians or higher in the oncology department, who were deemed unsuitable for or refused local treatments such as radiation therapy or surgery, who had a Karnofsky Performance Status score ≥ 70 points, who had an expected survival time ≥ 3 months, and who had a normal platelet count and coagulation function were included in the study. This study was approved by the Medical Ethics Committee of our hospital.

Table 1

Composition of lung tumors from different primary sources and pathological types
Primary disease type	Cases	Pathological type	No. of cases
Lung cancer	50	Carcinoma	77
Metastatic lung cancer	35	Sarcoma	8

1.2 Materials and Methods

The Prowess 3D Version 3.02 close-range treatment planning system (TPS; SSGI, Chico, CA, USA) was used in this study. The equipment used included an 1820-C implantation needle (diameter of 1.22 mm) and a Mick200-TPV20 cm implantation gun (Mick Radio-Nuclear Instruments, Inc., NY, USA). Radioactive iodine-125 seeds, with a γ-ray energy range of 27–35 keV, a radioactive activity of 0.4–0.8 mCi, and a half-life of 59.4 days, were provided by Atomic High Technology Co., Ltd. Preoperative enhanced chest CT scans were routinely performed within one week before iodine-125 seed implantation, and the CT scan data were transferred to the TPS to delineate the 90% dose curve of the target area, including the tumor target volume, and to calculate the number and spatial distribution of the implanted iodine-125 seeds. According to the TPS treatment plan, the prescription dose D90 was set to ≥ 80 Gy. Timely CT scans were obtained during the implantation process to ensure proper positioning of the seeds according to the TPS. Postoperative symptomatic treatments, such as electrocardiographic monitoring, oxygen therapy, and hemostasis, were administered. Closed thoracic drainage was performed for patients with significant pneumothorax.

1.3 Follow-up and efficacy evaluation

Enhanced chest CT scans were performed at 1, 3, and 6 months postoperatively to monitor changes in tumor size. The follow-up period was ≥ 6 months. The local efficacy evaluation of the tumor was based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), as follows [9]: complete response (CR) referred to the complete disappearance of the tumor, with imaging examinations showing no evidence of the tumor or only linear or thread-like images; partial response (PR) referred to a tumor shrinkage of ≥ 50%; stable disease (SD) referred to an increase in tumor size of no more than 25% or a shrinkage of less than 50%; and progressive disease (PD) referred to an increase in tumor size of more than 25% or the appearance of new lesions.

1.4 Statistical analysis

The data were analyzed using SPSS version 25.0 (IBM, Armonk, NY, USA). Independent sample t tests were used to analyze the dose–response relationships between the treatment efficacy groups. The optimal D90 threshold of the postoperative dose was determined by constructing a receiver operating characteristic (ROC) curve. The chi-square test was used to analyze the correlation between various factors and treatment efficacy. Univariate logistic regression analysis was performed for clinical and pathological factors, and binary logistic regression was used for multivariate analysis to evaluate independent prognostic factors. A P value < 0.05 was considered to indicate statistical significance.

1. Follow-up

As of September 30, 2021, all 85 patients were followed up for ≥ 6 months. The local control status of the patients at six months after seed implantation was as follows: 27 (31.76%) achieved CR, 33 (38.82%) achieved PR, 16 (18.82%) showed SD, and 9 (10.59%) showed PD. The CR rate was 31.76% (27/85), the overall response rate was 70.59% (60/85), and the disease control rate was 89.41% (76/85).

2. Clinical efficacy and analysis

2.1 For patients with lung cancer, the postoperative dose D90 in the CR group was 138.70 ± 19.14 Gy, while in the non-CR group (PR + SD + PD), it was 118.33 ± 28.62 Gy. The difference in postoperative dose D90 between the CR group and the non-CR group was statistically significant (t = 2.34, P = 0.024). For patients with metastatic lung cancer, the postoperative dose D90 in the CR group was 151.33 ± 41.49 Gy, while in the non-CR group (PR + SD + PD), it was 116.76 ± 25.90 Gy. The difference in postoperative dose D90 between the CR and non-CR groups was statistically significant (t = 2.95, P = 0.006). There was no statistically significant difference in the postoperative D90 between the CR group of patients with lung cancer and the CR group of patients with metastatic lung cancer (t = 0.99, P = 0.335). Similarly, there was no statistically significant difference in the postoperative D90 between the non-CR group of patients with lung cancer and the non-CR group of patients with metastatic lung cancer (t = 0.2, P = 0.839) (Table 2).

Table 2

Comparison of postoperative D90 dose between the complete response (CR) group and the non-CR group for lung tumors originating from different types of primary cancers
Primary disease origin	CR group D90 (Gy)		t	P
Lung cancer	138.70 ± 19.14	118.33 ± 28.62	2.34	0.024
Lung metastases	151.33 ± 41.49	116.76 ± 25.90	2.95	0.006
Lung cancer CR vs metastatic CR			0.99	0.335
Lung cancer non-CR vs metastatic non-CR			0.2	0.839

When we combined the CR group patients with lung cancer and metastatic lung cancer and compared them with the non-CR group patients with lung cancer and metastatic lung cancer, we observed a statistically significant difference in D90 between the combined CR and non-CR groups (t = 3.94, P = 0.00; Table 3). The optimal thresholds for postoperative D90 and the CR rate were obtained by creating an ROC curve, with an area under the curve of 0.749. The maximum Youden index corresponded to a postoperative D90 of 140.46 Gy (Fig. 1). When comparing groups based on a postoperative D90 cutoff of 140 Gy, the CR rates for the D90 ≥ 140 Gy and D90 < 140 Gy groups were 60.71% (17/28) and 17.54% (10/57), respectively, and the difference was statistically significant (χ² = 16.14, P = 0.0001; Table 4).

Table 3

Comparison of postoperative D90 dose between the combined complete response (CR) and non-CR groups
Primary disease origin	Combined CR group D90 (Gy)	Combined non-CR group D90 (Gy)	t	P
Lung cancer + lung metastases	145.25 ± 33.30	117.77 ± 27.67	3.94	0.00

Table 4

Comparison of CR and non-CR patients based on a postoperative D90 cutoff of 140 Gy
Postoperative D90	CR	non-CR	Rate(%)		χ²	P
<140Gy group	10	47		17.54	16.14	0.0001
≥ 140Gy group	17	11		60.71	16.14	0.0001

2.2 Analysis of the correlation between postoperative local control and clinical characteristics

In this study, we categorized general patient information, tumor histopathological classification, the tumor microenvironment, and treatment into seven clinicopathological factors and performed univariate analysis to examine their associations with the postoperative CR rate six months after seed therapy. The results showed that both tumor size (χ² = 16.28, P = 0.0001) and postoperative D90 (χ² = 16.14, P = 0.0001) significantly influenced the effectiveness of seed therapy (Table 5). However, age, sex, pathological type, preoperative hemoglobin level, and whether combined treatment was administered did not significantly differ. When factors such as tumor size, postoperative D90, and whether combined treatment was administered were included in a binary logistic analysis, tumor size (P = 0.0003) and postoperative D90 (P = 0.0005) were found to be independent prognostic factors for postoperative CR.

Table 5

Univariate analysis of the postoperative 6-month complete response rate in 85 patients with seed pulmonary tumors treated with seed therapy
Characteristic	Cases	CR	Non-CR	Chi-square value	P
Sex				1.58	0.208
Male	64	18	46
Female	21	9	12
Age (y)
< 65	41	13	28	0	0.991
≥ 65	44	14	30
Preoperative hemoglobin (g/L)				0.08	0.775
< 120	39	13	26
≥ 120	46	14	32
Pathological type				1.51	0.219
Carcinoma	77	26	51
Sarcoma	8	1	7
Tumor size (cm)				16.28	0.0001
< 4	42	22	20
≥ 4	43	5	38
Postoperative D90 (Gy)				16.14	0.0001
< 140	57	10	47
≥ 140	28	17	11
Combined treatment			0.19	0.663
Yes	47	14	33
No	38	13	25

2.3 Complications

Among the patients who underwent seed implantation, 43 had pneumothorax, accounting for 51.4% (43/85) of the total cases. Of these, 12 patients were classified as having small pneumothorax, which resolved spontaneously without symptomatic intervention. For the remaining 31 patients, closed thoracic drainage was performed, and the drainage tube was removed after three days. Bleeding was reported in three patients: two with pulmonary bleeding and one with hemoptysis. Symptomatic hemostasis was administered, and relief was achieved within two days. Additionally, there was one case of subcutaneous hematoma, which resolved on its own within two days. No significant pain, tumor implantation metastasis, air embolism, or radiation pneumonitis was observed postoperatively.

Lung cancer has the highest morbidity and mortality rates among malignant tumors in China [10]. Due to the lack of early diagnosis, nearly 75% of patients are already in the middle and late stages when they first seek medical attention, and more than half of these patients, including those with recurrent lung cancer and lung metastasis, miss the optimal window for surgery [11]. Studies have shown that metastasis accounts for more than 90% of tumor-related deaths, and 30–40% of patients with malignant tumors will develop lung metastasis [12, 13]. With the clinical application of the TPS system, iodine-125 radioactive seed implantation, a minimally invasive and effective brachytherapy method, has been widely used for various tumors, such as lung cancer, prostate cancer, and liver cancer [14–17]. Numerous studies have shown that seed implantation therapy is highly effective and safe for treating lung cancer and lung metastasis. This article reviews and analyses studies on the treatment of lung tumors with iodine-125 seed implantation, focusing on the relationship between local efficacy and dose.

This study revealed that the local control rate of seed implantation therapy was 89.41% (76/85), the total effective rate (CR + PR) was 70.59% (60/85), and the CR rate was 31.76% (27/85). Wang Z et al. reported a 6-month local control rate of 85.18% and an effective rate of 48.14% for patients with lung cancer. Although the local control rate was consistent with our findings, the effective rate was significantly lower than that in our study [18]. Another study by Li et al. showed that with an average D90 value of 132 Gy for seed implantation, the 6-month local control rate for patients with pulmonary metastases was 87.69%, and the effective rate was 78.46%. The local control rate was similar to ours, but the effective rate was greater [19]. Li et al. [20] reported that the local control rate of iodine-125 brachytherapy combined with sorafenib for treating liver cancer patients with lung metastasis was 82.4%, which was lower than the rate observed in our study. Vogl et al. [21] compared the local control rates of laser ablation, radiofrequency ablation, and microwave ablation for treating pulmonary metastases from colorectal cancer, reporting rates of 68%, 69.2%, and 88.3%, respectively. The local control rate of seed implantation therapy in our study was comparable to that observed with microwave ablation. While there are numerous studies on the local effective rate and control rate of minimally invasive tumor treatments, few studies have focused on the local complete remission rate. This study analyzed the relationship between the local complete remission rate and dose after seed implantation.

Our analysis suggested that the dose threshold obtained through the ROC curve for achieving CR after seed implantation for lung tumors is 140 Gy. This means that the local CR rate of the tumor significantly increases when a prescribed dose of 140 Gy or more is administered during seed implantation. This dose is equivalent to a biological equivalent dose of 146.40 Gy, and when converted into conventional radiotherapy of 2 Gy fractions, it is equivalent to an external exposure dose of 87.84 Gy. The 2021 National Comprehensive Cancer Network (NCCN) guidelines recommend that the biological equivalent dose for stereotactic ablative radiotherapy for non-small cell lung cancer (NSCLC) should be more than 100 Gy for effective local control [22]. This study showed that a biologically equivalent dose of 146 Gy or more can achieve better local efficacy. The recommended dose for conventional radiotherapy for NSCLC in the 2021 National Comprehensive Cancer Network (NCCN) guidelines is 60–70 Gy, and dose escalation is associated with better survival [22]. From a radiobiological perspective, NSCLC is moderately sensitive to radiation, and studies suggest that a dose of more than 84 Gy is required for more than 50% local control of NSCLC with conventional radiotherapy. However, owing to the limitation of lung tissue tolerance, achieving a dose of more than 60 Gy in conventional radiotherapy is already difficult [23, 24]. Radioactive iodine-125 seeds can increase the local tumor absorption dose while reducing radiation doses to adjacent critical organs in the surrounding tissue due to their unique radiobiological characteristic of a high dose gradient. Therefore, extremely high irradiation doses can be administered to the tumor tissue. This study confirmed that the administration of a prescribed dose of 140 Gy or more can significantly improve the CR rate in patients with lung cancer and lung metastases.

Studies have shown that the prognosis for lung cancer tumors larger than 4 cm differs significantly from that for tumors smaller than 4 cm [25]. Multiple studies have identified tumor size as a prognostic factor for the efficacy of radiotherapy, which is consistent with the results of this study [26]. A possible reason is that as tumors grow, interstitial invasion becomes more obvious, leading to hypoxia within the tumor cells. This hypoxia results in radiation resistance and poor radiotherapy outcomes due to inadequate blood supply. In this study, both univariate and multivariate analyses revealed that postoperative D90 (with 140 Gy as the cutoff point) and tumor size were independent prognostic factors for achieving a 6-month CR after lung tumor seed implantation. However, this study has limitations such as a small sample size and a lack of long-term follow-up studies; hence, further research and analysis are warranted.

In conclusion, radioactive seed implantation therapy is a safe and effective method for achieving local control of pulmonary tumors. This study further revealed that administering a prescribed dose of 140 Gy or more can lead to complete remission of local tumors, which is crucial for symptom relief and long-term survival. However, owing to the limited number of patients and a lack of long-term follow-up data, further research and analysis are needed to better understand the efficacy of this treatment.

PET-CT positron emission tomography

TPS treatment planning system

CR complete response

PR partial response

SD stable disease

PD progressive disease

D90 minimum peripheral dose received by the 90% target volume

ROC curve receiver operating characteristic curve

Funding：Not applicable

Author information

Authors and Affiliations

Department of Oncology, Hebei General Hospital, Shijiazhuang, 050051, P. R. China

Guohui Cao

Department of Radiotherapy, the Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China, P. R. China

Xiaojing Chang

Department of Oncology, Hebei General Hospital, Shijiazhuang, 050051, P. R. China

Zeyang Wang, Xiaoli Liu, Ke Xu, Juan Wang & Hongtao Zhang

Contributions

G. Cao, H. Zhang and J. Wang participated in study conception and design. G. Cao, X. Liu and K. Xu performed acquisition of data. G. Cao, X. Chang and Z. Wang performed analysis and interpretation of data. G. Cao, X. Chang participated in drafting of the article. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Hongtao Zhang.

Ethics declarations

Ethics approval and consent to participate：

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Hebei General Hospital Ethics Committee. Written informed consent was obtained from individual or guardian participants.

Consent for publication：Not applicable

Competing interests：The authors declare no competing interests

Siegel RL, Giaquinto AN, Jemal A, Cancer statistics. 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12–49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. PMID: 38230766.
He Y, Liang D, Li D, et al. Incidence and mortality of laryngeal cancer in China, 2015. Chin J Cancer Res. 2020;32(1):10–7. 10.21147/j.issn.1000-9604.2020.01.02. PMID: 32194300; PMCID: PMC7072018.
Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA Cancer J Clin. 2020;70(1):7–30. 10.3322/caac.21590. Epub 2020 Jan 8. PMID: 31912902.
Stella GM, Kolling S, Benvenuti S, et al. Lung-Seeking Metastases. Cancers (Basel). 2019;11(7):1010. 10.3390/cancers11071010. PMID: 31330946; PMCID: PMC6678078.
Mohammed TL, Chowdhry A, Reddy GP, et al. ACR Appropriateness Criteria® screening for pulmonary metastases. J Thorac Imaging. 2011;26(1):W1–3. 10.1097/RTI.0b013e3182010bf9. PMID: 21258219.
Ji Z, Ni Y, He C, et al. Clinical outcomes of radioactive seed brachytherapy and microwave ablation in inoperable stage I non-small cell lung cancer. Am J Cancer Res. 2023;13(8):3753–62. PMID: 37693146; PMCID: PMC10492108.
Han HM, Zhao XX, Shi LJ et al. [Clinical efficacy and safety analysis of ¹²⁵I seed implantation in the treatment of mediastinal lymph node metastasis of lung cancer]. Zhonghua Yi Xue Za Zhi. 2023;103(23):1781–1786. Chinese. 10.3760/cma.j.cn112137-20221205-02573. PMID: 37305938.
Wang Y, Zhu L, Lin X, et al. [Therapeutic Effect of CT-guided ¹²⁵I Seed Implantation on Advanced Lung Cancer and Pulmonary Metastatic Carcinoma]. Zhongguo Fei Ai Za Zhi. 2020;23(6):424–8. 10.3779/j.issn.1009-3419.2020.103.04. Chinese.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).[J]. Eur J Cancer. 2009;45(2):0–247. 10.1016/S1359-6349(09)70018-7.
Freddie, Bray,Jacques., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.[J].CA: a cancer journal for clinicians, 2018.10.3322/caac.21492.
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. 10.21147/j.issn.1000-9604.2018.01.01. PMID: 29545714; PMCID: PMC5842223.
Wu G, Woodruff HC, Shen J, et al. Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study[J]. Radiology. 2020;297(2):E282–282. 10.1148/radiol.2020209019.
Daskalaki A, Xenaki S, Athanasakis E, et al. Advanced Mesodermal (Müllerian) Adenosarcoma of the Ovary: Metastases to the Lungs, Mouth, and Brain[J]. Case Rep Surg. 2015;2015(10):403431. 10.1155/2015/403431.
Li H, Li W, Zhang L et al. Combination Treatment with Iodine 125 Seeds Implant and Systemic Therapy vs. Systemic Therapy Alone for Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. J Coll Physicians Surg Pak. 2023;33(1):84–91. 10.29271/jcpsp.2023.01.84. PMID: 36597241.
Li C, Zhang M, Wang J et al. The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients. Invest New Drugs. 2022;40(3):660–667. doi: 10.1007/s10637-021-01189-0. Epub 2022 Feb 12. Erratum in: Invest New Drugs. 2022;40(5):1164. 10.1007/s10637-022-01273-z. PMID: 35150357; PMCID: PMC9098556.
Chen X, Zhu F, Wang B, et al. Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood. J Oncol. 2021;2021:6199732. 10.1155/2021/6199732. PMID: 34367285; PMCID: PMC8342174.
Li J, Zhang L, Sun Z, et al. Iodine-125 seed implantation treatment of lung metastases < 2.5 cm using 5-ml syringe as a guide. J Contemp Brachytherapy. 2020;12(4):335–42. 10.5114/jcb.2020.98112. Epub 2020 Aug 21. PMID: 33293972; PMCID: PMC7690223.
Wang Z, Chen S, Su M et al. Analysis of the clinical efficacy and safety of computerized tomography-guided 125 I seed implantation in the treatment of non-small cell lung cancer that relapsed after chemoradiotherapy. J Cancer Res Ther. 2022;18(2):426–431. 10.4103/jcrt.jcrt_1660_21. PMID: 35645110.
Li J, Zhang L, Xu W, et al. Computed tomography-guided implantation of ¹²⁵I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results. J Contemp Brachytherapy. 2017;9(2):132–8. 10.5114/jcb.2017.67023. Epub 2017 Apr 3. PMID: 28533801; PMCID: PMC5437081.
Li C, Zhang F, Zhang W, et al. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(11):1633–40. 10.1007/s00432-010-0821-z. Epub 2010 Feb 21. PMID: 20865361.
Vogl TJ, Eckert R, Naguib NN, et al. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation. AJR Am J Roentgenol. 2016;207(6):1340–9. Epub 2016 Sep 28. PMID: 27680945.
NCCN clinical practice guidelines in oncology: non-small cell lung cancer (2021 version 1). (2020-11-25). URL: https://www.nccn.org/professionals/physician_gls/.
Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001;19(1):127 – 36. doi: 10.1200/JCO.2001.19.1.127. PMID: 11134205.
Martel MK, Ten Haken RK, Hazuka MB et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24(1):31 – 7. 10.1016/s0169-5002(99)00019-7. PMID: 10403692.
Rami-Porta R, Bolejack V, Crowley J et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990–1003. 10.1097/JTO.0000000000000559. PMID: 26134221.
Wang J, Wang T, Yang Y, et al. Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer[J]. Mol Clin Oncol. 2015. 10.3892/mco.2014.465.

No competing interests reported.

Download PDF

Editorial decision: Revision requested
30 Jul, 2024
Editor assigned by journal
30 Jul, 2024
Submission checks completed at journal
23 Jul, 2024
First submitted to journal
06 Jul, 2024

You are reading this latest preprint version

Dose and local efficacy analysis of iodine-125 seed implantation therapy for lung tumors

Status:

Version 1

Abstract

Objective

Methods

Results

Conclusion

Figures

Introduction

Data and Methods

1.1. Clinical Data

1.2 Materials and Methods

1.3 Follow-up and efficacy evaluation

1.4 Statistical analysis

Results

1. Follow-up

2. Clinical efficacy and analysis

Discussion

Conclusions

Abbreviations

Declarations

References

Additional Declarations

Status:

Version 1